MedPath

Angion Biomedica Corp.

Angion Biomedica Corp. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
1998-01-01
Employees
101
Market Cap
-
Website
http://www.angion.com

Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack

Phase 2
Terminated
Conditions
Myocardial Infarction
Interventions
Drug: Normal saline
First Posted Date
2012-02-27
Last Posted Date
2014-11-21
Lead Sponsor
Angion Biomedica Corp
Target Recruit Count
5
Registration Number
NCT01539590
Locations
🇺🇸

Yale University Medical Center, New Haven, New York, United States

🇺🇸

Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States

Study to Improve Renal Function After Kidney Transplantation

Phase 2
Conditions
Delayed Graft Function
Interventions
First Posted Date
2011-01-31
Last Posted Date
2015-05-05
Lead Sponsor
Angion Biomedica Corp
Target Recruit Count
30
Registration Number
NCT01286727
Locations
🇺🇸

Medstar Georgetown University Hospital, Washington, District of Columbia, United States

🇺🇸

Division of Transplant Surgery, University of Maryland School of Medicine, University of Maryland Medical Center, Baltimore, Maryland, United States

🇺🇸

California Institute of Renal Research, San Diego, California, United States

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath